Our range of products include clenash 80mg tablet, silagra 100 mg and rascase 1.5mg injection usa fast delivery.
₹ 260 / Strip Get Latest Price
| Brand | Clenash |
| Strength | 80 mcg |
| Packaging Size | 1*10 |
| Usage/Application | Athletic Performance |
| Form | Tablet |
| Packaging Type | Blister Pack |
| Pharmacopoeia Standard | EP |
| Manufacture | Asher Pharna |
₹ 152 / Strip Get Latest Price
| Strength (Sildenafil) | 100mg |
| Also Contains | Sildenafil (100mg) |
| Form | Tablet |
| Tablets per Strip | 10 Tablets |
| Brand Name | Suhagra |
| Additional Strength | 100mg |
| Prescribed For | Men |
| Manufacturer | Sunrise Remedies |
₹ 11599 / Vial Get Latest Price
| Packaging Type | Vial |
| Brand Name | Rascase 1.5 mg |
| Generic Name | Rasburicase |
| Strength | 1.5 mg per vial (lyophilized powder for injection) |
| Form | Lyophilized powder |
| Route of Administration | Intravenous infusion only (Must be diluted and administered by a healthcare professional) |
| Class | Enzyme Uric acid reducer |
| Mechanism | Catalyzes conversion of uric acid allantoin (water-soluble, easily excreted) |
| Storage | Store in a cool and dry place |
| Inactive Ingredients | Sodium phosphate monobasic Sodium phosphate dibasic Polysorbate 80 |
| Packaging. | Supplied in a single-dose glass vial containing 1.5 mg of rasburicase as a dry powder |
| Fast shipping | World wide |
Treatment of High Uric Acid Due to Chemotherapy: Certain cancers, such as leukemia, lymphoma, and solid tumors, can cause rapid cell turnover during chemotherapy, leading to the release of large amounts of uric acid into the bloodstream. Elevated uric acid levels can crystallize in the kidneys, causing damage. Rascas 1.5mg Injection contains rasburicase, an enzyme that converts uric acid into allantoin, a more soluble compound that is easily excreted by the kidneys, thereby reducing uric acid levels and preventing kidney damage.
Mechanism of Action: Rasburicase, the active ingredient in Rascas, is a recombinant form of the enzyme urate oxidase. It catalyzes the conversion of uric acid into allantoin, which is more water-soluble and can be readily eliminated by the kidneys. This process helps lower serum uric acid levels, reducing the risk of complications associated with hyperuricemia.
Administration: Rascas 1.5mg Injection is administered intravenously by a healthcare professional. It is not for self-administration.
Monitoring: Regular monitoring of uric acid levels, kidney function, and overall patient status is essential during treatment.
Contraindications: Rascas is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it may lead to hemolysis.
Pregnancy and Breastfeeding: The use of Rascas during pregnancy and breastfeeding is generally not recommended due to potential risks to the fetus or infant.
SKYBLUE INTERNATIONAL (CEO)
Skyblue International
Basement Floor, House No 1568/G-6a, Plot No 51-B, Shop No 6, Sai Plaza, Shastri Nagar Chowk Road, Baba Saheb Ambedkar Chowk, Near Indian Bank
Nagpur - 440008, Maharashtra, India